FULVICIN P/G 165 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Fulvicin P/g 165, and what generic alternatives are available?
Fulvicin P/g 165 is a drug marketed by Chartwell Rx and is included in one NDA.
The generic ingredient in FULVICIN P/G 165 is griseofulvin, ultramicrosize. There is one drug master file entry for this compound. Five suppliers are listed for this compound. Additional details are available on the griseofulvin, ultramicrosize profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Fulvicin P/g 165
A generic version of FULVICIN P/G 165 was approved as griseofulvin, ultramicrosize by MOUNTAIN on January 9th, 2014.
Summary for FULVICIN P/G 165
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 96 |
Patent Applications: | 4,531 |
Formulation / Manufacturing: | see details |
DailyMed Link: | FULVICIN P/G 165 at DailyMed |
Pharmacology for FULVICIN P/G 165
Drug Class | Tubulin Inhibiting Agent |
Physiological Effect | Decreased Mitosis Microtubule Inhibition |
Anatomical Therapeutic Chemical (ATC) Classes for FULVICIN P/G 165
US Patents and Regulatory Information for FULVICIN P/G 165
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chartwell Rx | FULVICIN P/G 165 | griseofulvin, ultramicrosize | TABLET;ORAL | 061996-003 | Apr 6, 1982 | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |